HC Wainwright Issues Optimistic Forecast for ASMB Earnings

Assembly Biosciences, Inc. (NASDAQ:ASMB) – Investment analysts at HC Wainwright increased their Q1 2025 earnings per share estimates for Assembly Biosciences in a report issued on Monday, March 24th. HC Wainwright analyst E. Arce now forecasts that the biopharmaceutical company will earn ($1.54) per share for the quarter, up from their previous estimate of ($1.95). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Assembly Biosciences’ current full-year earnings is ($6.87) per share. HC Wainwright also issued estimates for Assembly Biosciences’ Q2 2025 earnings at ($1.54) EPS, Q3 2025 earnings at ($1.64) EPS, Q4 2025 earnings at ($1.57) EPS, FY2025 earnings at ($6.29) EPS, FY2026 earnings at ($9.05) EPS, FY2027 earnings at ($12.07) EPS and FY2028 earnings at ($12.32) EPS.

Assembly Biosciences (NASDAQ:ASMB) last posted its quarterly earnings data on Thursday, March 20th. The biopharmaceutical company reported ($1.57) earnings per share for the quarter, topping the consensus estimate of ($1.75) by $0.18. The firm had revenue of $7.36 million during the quarter, compared to analysts’ expectations of $7.05 million. Assembly Biosciences had a negative net margin of 144.05% and a negative return on equity of 121.46%.

Several other equities research analysts have also recently commented on the stock. StockNews.com cut shares of Assembly Biosciences from a “buy” rating to a “hold” rating in a research report on Monday. Guggenheim initiated coverage on shares of Assembly Biosciences in a research note on Tuesday. They issued a “buy” rating and a $31.00 price objective on the stock.

Assembly Biosciences Stock Up 2.7 %

Shares of ASMB stock opened at $11.42 on Wednesday. Assembly Biosciences has a 12 month low of $10.27 and a 12 month high of $19.93. The firm has a market cap of $72.59 million, a price-to-earnings ratio of -1.70 and a beta of 0.62. The stock has a 50-day moving average price of $12.77 and a 200 day moving average price of $15.05.

Insider Transactions at Assembly Biosciences

In other news, Director Michael Houghton acquired 3,202 shares of Assembly Biosciences stock in a transaction that occurred on Monday, December 30th. The shares were acquired at an average price of $15.61 per share, with a total value of $49,983.22. Following the purchase, the director now directly owns 3,202 shares of the company’s stock, valued at $49,983.22. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 5.10% of the company’s stock.

Hedge Funds Weigh In On Assembly Biosciences

Hedge funds and other institutional investors have recently made changes to their positions in the company. Marshall Wace LLP raised its stake in Assembly Biosciences by 16.5% during the 4th quarter. Marshall Wace LLP now owns 14,823 shares of the biopharmaceutical company’s stock worth $234,000 after buying an additional 2,098 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of Assembly Biosciences by 5,137.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 3,509 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 3,442 shares in the last quarter. FMR LLC grew its position in shares of Assembly Biosciences by 29.7% in the 3rd quarter. FMR LLC now owns 15,855 shares of the biopharmaceutical company’s stock valued at $240,000 after purchasing an additional 3,635 shares during the period. Palumbo Wealth Management LLC bought a new stake in Assembly Biosciences during the 4th quarter worth approximately $180,000. Finally, Man Group plc acquired a new stake in Assembly Biosciences during the 4th quarter worth approximately $309,000. 19.92% of the stock is owned by institutional investors.

About Assembly Biosciences

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.